

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Apr 2021 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Agalsidase Alfa	Replagal	Nutrition and blood	Pending	Pending further information
2	Belimumab	Benlysta	Musculoskeletal and joint diseases	Approved	
3	Cabozantinib	Cabometyx	Malignant disease and immunosuppression	Approved	
4	Dermatophagoides allergen extract	Acarizax	Respiratory system	Rejected	Insufficient evidence of long-term clinical outcome benefits
5	Entrectinib	Rozlytrek	Malignant disease and immunosuppression	Pending	Pending further information
6	Enzalutamide	Xtandi	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
7	Fulvestrant	Faslodex	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
8	Fulvestrant / Palbociclib	Faslodex / Ibrance	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
9	Gemtuzumab Ozogamicin	Mylotarg	Malignant disease and immunosuppression	Approved	
10	Lenalidomide	Revlimid	Malignant disease and immunosuppression	Pending	Pending further information
11	Liraglutide	Saxenda	Endocrine system	Approved	
12	Moroctocog alfa	Xyntha	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
13	Nonacog alfa	BeneFIX	Cardiovascular system	Rejected	Alternative(s) available in HADF with comparable benefits
14	Olaparib	Lynparza	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
15	Oxycodone	OxyContin / OxyNorm	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
16	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Pending	Pending further information
17	Pomalidomide	Pomalyst	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
18	Rituximab	MabThera	Malignant disease and immunosuppression	Approved	
19	Romozosumab	Evenity	Endocrine system	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
20	Siponimod	Mayzent	Malignant disease and immunosuppression	Approved	
21	Tafamidis	Vyndamax	Cardiovascular system	Pending	Pending further information
22	Thiotepa	Tepadina	Malignant disease and immunosuppression	Approved	
23	Trifluridine/tipiracil	Lonsurf	Malignant disease and immunosuppression	Approved	
24	Upadacitinib	Rinvoq	Musculoskeletal and joint diseases	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.